JP2020524143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524143A5 JP2020524143A5 JP2019569758A JP2019569758A JP2020524143A5 JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5 JP 2019569758 A JP2019569758 A JP 2019569758A JP 2019569758 A JP2019569758 A JP 2019569758A JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- bioactive agent
- lipid
- oil
- sorbitan ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 239000012867 bioactive agent Substances 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 15
- 239000004094 surface-active agent Substances 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- -1 sorbitan ester Chemical class 0.000 claims 13
- 239000007791 liquid phase Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 239000007790 solid phase Substances 0.000 claims 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 229940031439 squalene Drugs 0.000 claims 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical group CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000001294 propane Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 2
- 239000001587 sorbitan monostearate Substances 0.000 claims 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940113164 trimyristin Drugs 0.000 claims 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229940044606 RIG-I agonist Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000010775 animal oil Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 150000002313 glycerolipids Chemical class 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 claims 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000126A JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520204P | 2017-06-15 | 2017-06-15 | |
| US62/520,204 | 2017-06-15 | ||
| US201762540973P | 2017-08-03 | 2017-08-03 | |
| US62/540,973 | 2017-08-03 | ||
| US201762556291P | 2017-09-08 | 2017-09-08 | |
| US62/556,291 | 2017-09-08 | ||
| US201762563544P | 2017-09-26 | 2017-09-26 | |
| US62/563,544 | 2017-09-26 | ||
| US201762582859P | 2017-11-07 | 2017-11-07 | |
| US62/582,859 | 2017-11-07 | ||
| US201862622748P | 2018-01-26 | 2018-01-26 | |
| US201862622755P | 2018-01-26 | 2018-01-26 | |
| US62/622,748 | 2018-01-26 | ||
| US62/622,755 | 2018-01-26 | ||
| US201862669262P | 2018-05-09 | 2018-05-09 | |
| US62/669,262 | 2018-05-09 | ||
| US201862677336P | 2018-05-29 | 2018-05-29 | |
| US62/677,336 | 2018-05-29 | ||
| US201862680454P | 2018-06-04 | 2018-06-04 | |
| US62/680,454 | 2018-06-04 | ||
| PCT/US2018/037783 WO2018232257A1 (en) | 2017-06-15 | 2018-06-15 | Nanostructured lipid carriers and stable emulsions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000126A Division JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524143A JP2020524143A (ja) | 2020-08-13 |
| JP2020524143A5 true JP2020524143A5 (enExample) | 2021-07-29 |
Family
ID=62948328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569758A Pending JP2020524143A (ja) | 2017-06-15 | 2018-06-15 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11141377B2 (enExample) |
| EP (1) | EP3638207B1 (enExample) |
| JP (2) | JP2020524143A (enExample) |
| KR (2) | KR20240096685A (enExample) |
| CN (1) | CN111315362A (enExample) |
| AU (1) | AU2018285694B2 (enExample) |
| BR (1) | BR112019026615B1 (enExample) |
| CA (1) | CA3067224A1 (enExample) |
| ES (1) | ES3003260T3 (enExample) |
| IL (1) | IL271384B2 (enExample) |
| MX (4) | MX2019015076A (enExample) |
| WO (1) | WO2018232257A1 (enExample) |
| ZA (1) | ZA201908207B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240096685A (ko) | 2017-06-15 | 2024-06-26 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| WO2020150274A1 (en) | 2019-01-15 | 2020-07-23 | Nant Holdings Ip, Llc | Aragonite compositions, methods, and uses thereof |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| EP4058581A1 (en) | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
| CN115955959A (zh) * | 2020-02-26 | 2023-04-11 | 康普萨姆公司 | 纳米结构脂质载体递送系统、组合物和方法 |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| CN111494619B (zh) * | 2020-04-26 | 2022-03-18 | 南京农业大学 | 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法 |
| CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
| AU2021335334A1 (en) | 2020-09-04 | 2023-04-20 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
| CA3173408A1 (en) | 2020-12-23 | 2022-06-30 | Access To Advanced Health Institute | Solanesol vaccine adjuvants and methods of preparing same |
| US20240252620A1 (en) * | 2021-05-28 | 2024-08-01 | The Regents Of The University Of Michigan | Combined agonist adjuvant for coronavirus vaccine |
| IN202121031414A (enExample) * | 2021-07-13 | 2023-01-13 | ||
| AU2022317127B2 (en) | 2021-07-29 | 2025-02-27 | Nantcell, Inc. | Modified t cell receptors for the prevention and treatment of viral infections and cancer |
| KR102681030B1 (ko) * | 2021-08-02 | 2024-07-02 | 한국화학연구원 | 올리고뉴클레오타이드가 봉입된 나노입자, 이의 제조방법 및 이를 포함하는 약학적 제제 |
| US20250134991A1 (en) * | 2021-08-20 | 2025-05-01 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| EP4404957A4 (en) * | 2021-09-22 | 2025-08-06 | Hdt Bio Corp | CANCER THERAPY COMPOSITIONS AND THEIR USES |
| EP4412621A2 (en) * | 2021-09-22 | 2024-08-14 | HDT Bio Corp. | Compositions and methods for enhanced protein production |
| EP4404977A4 (en) * | 2021-09-22 | 2025-07-30 | Hdt Bio Corp | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF |
| WO2023048759A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Sars-cov-2 rna vaccine compositions and methods of use |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
| WO2024053934A1 (ko) * | 2022-09-05 | 2024-03-14 | 주식회사 차백신연구소 | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 |
| CA3266697A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN |
| CN116159145B (zh) * | 2023-01-31 | 2025-04-22 | 四川大学 | 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用 |
| CN116392586B (zh) * | 2023-04-12 | 2025-06-24 | 江苏中慧元通生物科技股份有限公司 | 一种纳米乳佐剂 |
| WO2024216214A1 (en) * | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2025006870A1 (en) * | 2023-06-29 | 2025-01-02 | Rigimmune Inc. | Novel formulations |
| WO2025244961A1 (en) * | 2024-05-22 | 2025-11-27 | Merck Sharp & Dohme Llc | Processes for making stable nanoemulsion adjuvants |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
| JP3237842B2 (ja) | 1988-12-16 | 2001-12-10 | オランダ国 | ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| DK0414374T3 (da) | 1989-07-25 | 1998-03-09 | Smithkline Beecham Biolog | Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| DE122007000084I1 (de) | 1991-07-19 | 2008-03-27 | Univ Queensland St Lucia | Impfstoff gegen Humanes Papillomavirus (Typ 18) |
| EP0614465B1 (en) | 1991-11-16 | 1999-03-17 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
| DE122007000099I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
| US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| ATE492289T1 (de) | 1993-03-09 | 2011-01-15 | Univ Rochester | Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| PT809700E (pt) | 1994-10-07 | 2006-09-29 | Univ Loyola Chicago | Particulas semelhantes ao papilomavirus e proteinas de fusao, assim como metodos para a sua producao |
| WO1996026277A1 (en) | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| AR012035A1 (es) | 1997-02-25 | 2000-09-27 | Corixa Corp | Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| EP0998557A2 (en) | 1997-07-21 | 2000-05-10 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| WO1999028475A2 (en) | 1997-11-28 | 1999-06-10 | Genset | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| PT1584685E (pt) | 1998-02-05 | 2011-06-17 | Glaxosmithkline Biolog Sa | Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação |
| CA2326598C (en) | 1998-04-07 | 2014-06-10 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| EP1073734B1 (en) | 1998-04-15 | 2009-09-23 | Ludwig Institute for Cancer Research Ltd. | Tumor associated nucleic acids and uses therefor |
| AU762812B2 (en) | 1998-07-14 | 2003-07-03 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| TR200103018T2 (tr) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
| EP1322287B1 (en) | 2000-09-28 | 2006-03-22 | Chiron Corporation | Microparticles for delivery of the heterologous nucleic acids |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7998119B2 (en) | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| PT2484375T (pt) | 2006-09-26 | 2018-07-09 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| DK2136836T3 (en) | 2007-04-04 | 2017-04-10 | Infectious Disease Res Inst | Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof |
| WO2009088401A2 (en) * | 2007-09-24 | 2009-07-16 | Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Immunostimulatory combinations of tlr ligands and methods of use |
| HRP20161585T1 (hr) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže |
| SG10201407996PA (en) | 2009-12-23 | 2015-01-29 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| CN103327963A (zh) | 2010-07-06 | 2013-09-25 | 诺华股份有限公司 | 阳离子水包油乳液 |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| AU2012280904B2 (en) | 2011-07-06 | 2017-02-23 | Glaxosmithkline Biologicals S.A. | Cationic oil-in-water emulsions |
| CN103764121A (zh) * | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| US10322089B2 (en) * | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| US8809388B2 (en) * | 2012-11-06 | 2014-08-19 | Brandeis University | Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol |
| EP2943221A1 (en) * | 2013-01-10 | 2015-11-18 | Novartis AG | Influenza virus immunogenic compositions and uses thereof |
| WO2017201340A2 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
| KR20240096685A (ko) * | 2017-06-15 | 2024-06-26 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
-
2018
- 2018-06-15 KR KR1020247018651A patent/KR20240096685A/ko not_active Ceased
- 2018-06-15 US US16/622,908 patent/US11141377B2/en active Active
- 2018-06-15 JP JP2019569758A patent/JP2020524143A/ja active Pending
- 2018-06-15 MX MX2019015076A patent/MX2019015076A/es unknown
- 2018-06-15 KR KR1020207001253A patent/KR102673794B1/ko active Active
- 2018-06-15 CN CN201880050697.XA patent/CN111315362A/zh active Pending
- 2018-06-15 WO PCT/US2018/037783 patent/WO2018232257A1/en not_active Ceased
- 2018-06-15 BR BR112019026615-1A patent/BR112019026615B1/pt active IP Right Grant
- 2018-06-15 ES ES18742621T patent/ES3003260T3/es active Active
- 2018-06-15 AU AU2018285694A patent/AU2018285694B2/en active Active
- 2018-06-15 IL IL271384A patent/IL271384B2/en unknown
- 2018-06-15 EP EP18742621.8A patent/EP3638207B1/en active Active
- 2018-06-15 CA CA3067224A patent/CA3067224A1/en active Pending
-
2019
- 2019-12-10 ZA ZA2019/08207A patent/ZA201908207B/en unknown
- 2019-12-13 MX MX2023006661A patent/MX2023006661A/es unknown
- 2019-12-13 MX MX2022013322A patent/MX2022013322A/es unknown
- 2019-12-13 MX MX2022013320A patent/MX2022013320A/es unknown
-
2021
- 2021-09-09 US US17/470,874 patent/US12201722B2/en active Active
-
2024
- 2024-01-04 JP JP2024000126A patent/JP2024029173A/ja active Pending
- 2024-12-11 US US18/977,878 patent/US20250241854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524143A5 (enExample) | ||
| Chatzikleanthous et al. | Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines | |
| JP7333563B2 (ja) | 脂質ナノ粒子 | |
| JP7202009B2 (ja) | ｓｉＲＮＡ細胞内送達のための脂質膜構造体 | |
| Kim et al. | Nanotechnology and vaccine development | |
| Davidsen et al. | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses | |
| JP2013531680A5 (enExample) | ||
| DK2729127T3 (en) | METHODS FOR LIPOSOMES PREPARATION | |
| RU2014104092A (ru) | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты | |
| US20170049702A1 (en) | Method to Enhance an Immune Response of Nucleic Acid Vaccination | |
| US20110177156A1 (en) | Sterol-Modified Amphiphilic Lipids | |
| JP2023518976A (ja) | Ｒｎａを送達するための組成物および方法 | |
| EP3147277B1 (en) | Lipid membrane structure for sirna intracellular delivery | |
| Nordly et al. | Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo | |
| CN1980638B (zh) | 用糖脂稳定基于脂质的佐剂制剂的组合物和方法 | |
| Perrie et al. | Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route | |
| Wang et al. | Advances in the study of LNPs for mRNA delivery and clinical applications | |
| Ahmad et al. | Liposomes and niosomes for targeted drug and gene delivery systems | |
| WO2024209013A1 (en) | Lipid nanoparticle compositions | |
| Nie et al. | Synthetic nanomaterials for spleen-specific mRNA delivery | |
| Steffes et al. | Cryo-TEM Reveals the Influence of Multivalent Charge and PEGylation on Shape Transitions in Fluid Lipid Assemblies: From Vesicles to Discs, Rods, and Spheres | |
| Wölk et al. | Investigation of binary lipid mixtures of a three-chain cationic lipid with phospholipids suitable for gene delivery | |
| JP5390059B2 (ja) | 無菌ポリヌクレオチド系薬剤の製造方法 | |
| Porte et al. | A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity | |
| JPWO2018181542A1 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |